194414-69-2

Basic information

• Product Name: 20-O-camptothecin propionate ester
• CAS NO: 194414-69-2
• Molecular Weight: 404.422
• Mol File: 194414-69-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 20-O-camptothecin propionate ester(CAS DataBase Reference)
• NIST Chemistry Reference: 20-O-camptothecin propionate ester(194414-69-2)
• EPA Substance Registry System: 20-O-camptothecin propionate ester(194414-69-2)

Safety Data

• Hazardous Substances Data: 194414-69-2(Hazardous Substances Data)

Usage

Chemical compound

20-O-camptothecin propionate ester

Derivative of

camptothecin

Naturally occurring alkaloid found in

Chinese tree Camptotheca acuminata

Potential as

anti-cancer agent

Demonstrated

strong cytotoxic activity against a variety of cancer cell lines

Improved

water solubility and stability compared to parent compound

Viable option for

pharmaceutical development

Potential to be

effective anticancer drug

Further studies being conducted to explore

therapeutic applications

Source

tree Camptotheca acuminata

Upstream product

• 123-62-6 propionic acid anhydride 
• 7689-03-4 camptothecin 

Relevant articles and documents

Alkyl esters of camptothecin and 9-nitrocamptothecin: Synthesis, in vitro pharmacokinetics, toxicity, and antitumor activity

Eleven camptothecin esters, 6a-e and 7a-f, were prepared by straightforward acylation of camptothecins with the corresponding acylating reagents such as organic anhydrides and carboxylic acid chlorides. The in vitro pharmacokinetic determination of lacton

Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs

Derivatives of camptothecin as represented by the general formula: are described, wherein when R1is H, R. is a C2-C4alkyl group, a C6-C15alkyl group, a C3-C8cycloalkyl group, a C2-C15alkenyl group or a C2-C15epoxy group; and when R2is a nitro group or an amino group, R1is a C1-C15alkyl group, a C1-C15alkenyl group, a C3-C8cycloalkyl group, or an epoxy group. Liposomal prodrugs including these specific derivatives of camptothecin restrained by a liposomal delivery system are also described. Processes for making these prodrugs and for using them in cancer treatment are also disclosed.